Regeneron Pharmaceuticals, Inc. REGN

NAS: REGN | ISIN: US75886F1075   3/07/2025
547,36 USD (-0,07%)
(-0,07%)   3/07/2025
Grafiek Regeneron Pharmaceuticals, Inc. Grafiek Regeneron Pharmaceuticals, Inc.
vrijdag 1 augustus 2025, 12:30
Kwartaalcijfers (2de kwartaal)

Regeneron Pharmaceuticals, Inc. in het nieuws

12 maart 2025 · Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Research on Classifying Celestial Objects, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem · Persbericht

6 maart 2025 · Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit · Persbericht

5 maart 2025 · SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals · Persbericht

5 maart 2025 · CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Regeneron Pharmaceuticals (NASDAQ: REGN) Investors to Inquire About a Securities Fraud Class Action by March 10, 2025 · Persbericht

4 maart 2025 · Contact Levi & Korsinsky by March 10, 2025 Deadline to Join Class Action Against Regeneron Pharmaceuticals, Inc.(REGN) · Persbericht

29 mei 2024 · Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors · Persbericht

13 maart 2024 · High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization · Persbericht

24 januari 2024 · Top 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in Awards · Persbericht

8 januari 2024 · Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo® (cemiplimab) in Multiple Countries · Persbericht

19 mei 2023 · High School Scientists and Engineers Win Nearly $9 Million at the Regeneron International Science and Engineering Fair 2023 · Persbericht

Profiel Regeneron Pharmaceuticals, Inc.

Biotechnologie
Fabricage van farmaceutische preparaten
Gezondheidstechnologie
Productie

Website: www.regeneron.com

Hoofdzetel: Tarrytown, New York vlag Verenigde Staten

CEO: Leonard Schleifer

Werknemers: 12.099

Mijn selecties